We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

It recommends healthcare practitioners should offer a low-dose combination of inhaled corticosteroids (ICS) and formoterol to be taken as needed for everyone aged 12 and over with newly diagnosed ...

For further information on the guideline development process, please see how we develop NICE guidelines ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

These tools set cookies that store anonymised information about how you got to the site, and how you interact with the site.

See recommendations on pharmacological management in people aged 12 and over and the summary of pharmacological management in people aged 12 years and over in the BTS, NICE and SIGN guideline on ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

Eplontersen (Wainzua, AstraZeneca) is indicated for 'treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with stage 1 and 2 polyneuropathy'. The list price ...

Eplontersen is recommended, within its marketing authorisation, as an option for treating hereditary transthyretin-related amyloidosis in adults with stage 1 or stage 2 polyneuropathy. It is only ...

Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments TA1015 13 November 2024 13 November 2024 ...

The Appraisal Committee has prepared a Final Draft Guidance (FDG) on Eplontersen for treating hereditary transthyretin-related amyloidosis and submitted it to the Institute. The FDG has been sent to ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.